HCPCS code J7321: Hyaluronan injection

Key Takeaways

HCPCS Code J7321 describes hyaluronan or derivative (Hyalgan, Supartz, or Visco-3) for intra-articular injection, billed per dose, one unit per injection (Hyalgan 20 mg; Supartz and Visco-3 25 mg)

Always pair J7321 with CPT code 20610 for the injection administration; report the National Drug Code (NDC) on all Medicare Part B claims

Medicare reimburses J7321 under the ASP+6% Part B drug payment methodology; rates update quarterly and vary by payer

Pabau’s claims management software supports structured drug code billing workflows to reduce denials and streamline J7321 claim submission

HCPCS Code J7321 covers three widely used viscosupplementation products, and billing staff often encounter it as one of the highest-volume injectable drug billing codes in orthopedic and rheumatology settings.

The official HCPCS Level II description is: Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose.

J7321 sits within the HCPCS category “Drugs Administered Other than Oral Method” and is maintained by the Centers for Medicare and Medicaid Services (CMS). The code became effective for Visco-3 (Zimmer Biomet) on April 1, 2021, bringing it alongside the existing Hyalgan (Sanofi) and Supartz (Bioventus) products under a single code.

What J7321 is used for: Clinical context

Viscosupplementation involves injecting hyaluronic acid derivatives directly into a joint to supplement the natural synovial fluid in patients with osteoarthritis. J7321 covers three brand-name products that share the same active mechanism but differ in dosing schedules.

All three products under J7321 are FDA-approved for osteoarthritis of the knee only. Billing for other joint sites requires careful documentation of medical necessity and may not be covered under standard Medicare Local Coverage Determinations (LCDs).

• Hyalgan (Sanofi): sodium hyaluronate, typically administered as a 5-injection weekly course
• Supartz (Bioventus): sodium hyaluronate, typically a 5-injection weekly course
• Visco-3 (Zimmer Biomet): sodium hyaluronate, typically a 3-injection weekly course

The primary diagnosis code supporting J7321 claims is ICD-10-CM M17 (primary osteoarthritis, knee) or its subcategories. Payers using sports medicine software and orthopedic billing workflows commonly pair this diagnosis with J7321 for knee injection courses.

Per-dose vs. per-mg distinction

J7321 is a per-dose code, not a per-mg code. One billing unit equals one dose. The milligram amount per dose varies by product per FDA-approved labeling: Hyalgan is 20 mg (2 mL), while Supartz and Visco-3 are 25 mg (2.5 mL). Regardless of product, J7321 is billed as one unit per injection. This is a frequent source of coding confusion: billing staff occasionally attempt to calculate units based on milligrams, which leads to overbilling or underbilling. Bill one unit of J7321 for each injection encounter, regardless of product volume.

J7321 billing: CPT code pairing and claim structure

J7321 covers only the drug product. The injection administration itself requires a separate CPT code. Most practices pair J7321 with CPT code 20610 (arthrocentesis, aspiration, and/or injection of a major joint or bursa). Reviewing procedure code pairing rules for drug administration helps billing staff structure claims correctly the first time.

A correctly structured J7321 claim includes both codes on the same date of service for each injection visit. The CPT code triggers reimbursement for the physician’s work; the HCPCS code triggers reimbursement for the drug itself under the buy-and-bill model.

Place of service considerations

Place of service affects how J7321 is reimbursed. In an office setting (POS 11), the practice bills both 20610 and J7321, receiving payment for both the procedure and the drug. In an ambulatory surgical center (POS 24) or hospital outpatient department (POS 22), the facility typically bills the drug separately while the physician bills only the professional component of 20610. Confirming the correct setting with the payer before submitting prevents split-billing errors.

Practices using claims management software that tracks place of service automatically reduce the risk of these mismatches at submission.

NDC reporting requirements for J7321

CMS requires the National Drug Code (NDC) to be reported on all Medicare Part B drug claims, including J7321. Submitting J7321 without a valid NDC results in claim rejection under most Medicare Administrative Contractor (MAC) edits. This is a hard requirement, not a best practice suggestion.

The NDC must be reported in the following format on the CMS-1500 or 837P electronic claim: an 11-digit number in 5-4-2 format, a qualifier (N4), the unit of measure (UN for units), and the quantity dispensed. Practices managing multiple drug products benefit from prescription management software that stores and auto-populates NDC data at the point of prescribing.

• Hyalgan NDC example: Sanofi catalog numbers vary by package size; confirm from the product label or wholesaler invoice
• Supartz NDC: Bioventus catalog; confirm per lot at time of purchase
• Visco-3 NDC: Zimmer Biomet NHRIC catalog number; reported per the Zimmer Biomet Coding Reference Guide

The Zimmer Biomet HCPCS Level II Coding Reference Guide explicitly recommends billing Visco-3 claims showing both the J7321 HCPCS code and the NDC. Use the NDC from the actual product vial dispensed, not a generic catalog number. MACs conduct post-payment audits comparing NDC records against dispensing invoices.

Good digital documentation forms that capture lot numbers and NDCs at the point of care make it easier to populate claims accurately without chasing paper records after the fact.

Streamline your drug code billing with Pabau

Pabau's claims management tools help orthopedic and rheumatology practices structure J7321 claims correctly, track NDC data, and reduce denials before they reach the payer.

Book a demo

J7321 fee schedule and Medicare reimbursement rates

Medicare reimburses J7321 under the Part B drug payment methodology, which is Average Sales Price (ASP) plus 6%. Because ASP is recalculated quarterly by CMS, the reimbursement rate for J7321 changes four times per year. Practices should verify current rates directly through the CMS Physician Fee Schedule lookup or the quarterly ASP drug pricing files published on the CMS website before projecting drug acquisition costs against reimbursement.

The buy-and-bill model used for viscosupplementation means the practice purchases the drug at Wholesale Acquisition Cost (WAC) or Average Wholesale Price (AWP) from a distributor, administers it, and then seeks reimbursement at ASP+6% from Medicare. Practices with thin margins on these drugs should regularly compare acquisition cost against the current ASP reimbursement to avoid absorbing a loss per injection course.

Reviewing drug procedure fee schedules alongside payer contracts helps practices build accurate cost models for viscosupplementation programs.

Commercial and Medicaid payer differences

Commercial payers and state Medicaid programs do not follow the ASP+6% formula. Coverage and reimbursement for J7321 vary significantly across payers. Some commercial plans reimburse at a percentage of AWP; others apply a flat per-dose rate negotiated in the provider contract.

Medicaid in California (Medi-Cal), for example, publishes its own allowed amounts for J7321 in the Drugs and Biologicals fee schedule, which differ from Medicare rates.

UnitedHealthcare’s commercial medical benefit drug policy for sodium hyaluronate is a practical reference for understanding how one major commercial payer applies coverage criteria for J7321 and related products. Understanding HIPAA compliance for medical offices also informs how patient benefit information and remittance data should be handled securely across different payer portals.

Medicare coverage and LCD requirements for J7321

Medicare coverage for J7321 viscosupplementation is governed by Local Coverage Determinations (LCDs) rather than a national policy. Current LCDs for intra-articular hyaluronan knee injections include L39260 and L39529, each administered by specific Medicare Administrative Contractors (MACs) for their jurisdiction. Coverage criteria, covered ICD-10 codes, and documentation requirements under these LCDs typically include the following:

• Diagnosis of primary or secondary osteoarthritis of the knee (ICD-10-CM M17.x)
• Documentation of conservative treatment failure (physical therapy, NSAIDs, analgesics) prior to viscosupplementation
• Physician documentation confirming the medical necessity of the injection for this specific patient
• Limitation to the knee joint (other joints are not covered under most LCDs)

Because LCDs are jurisdiction-specific, practices should verify which MAC administers their region and pull the current LCD version. The CMS Medicare Coverage Database is the authoritative source. Reviewing medical necessity documentation standards across different code types reinforces the documentation discipline that LCD compliance requires.

Per the CMS HCPCS overview, HCPCS Level II codes like J7321 are maintained annually, and coverage changes can take effect mid-year through transmittals. Billing teams should subscribe to MAC listservs to catch LCD revisions before they cause denials.

Related HCPCS codes for viscosupplementation

J7321 is one of several HCPCS codes covering distinct hyaluronic acid products used in viscosupplementation. Selecting the wrong code is one of the most common billing errors in this category, particularly as products change manufacturers or new formulations enter the market. Procedure code reference guides for drug injection billing consistently emphasize the importance of verifying product-specific code assignments.

The key distinction between J7321 (per dose) and per-mg codes elsewhere in the J-code series is billing unit logic. Never substitute J7321 for a product it does not cover. If the provider switches from Hyalgan to Euflexxa mid-course, the billing code must change to J7323 for the remaining injections.

NCCI edits and modifier considerations

National Correct Coding Initiative (NCCI) edits can bundle 20610 with other evaluation and management (E/M) codes billed on the same day. If a significant, separately identifiable E/M service is provided at the same visit, append modifier 25 to the E/M code.

Modifier 59 (or an X-modifier) may be needed when billing multiple procedures that are bundled by NCCI edits. Confirm current edit pairs through the AAPC Codify HCPCS lookup before finalizing claim structure.

Common J7321 denial reasons and documentation checklist

Most J7321 denials trace back to four recurring gaps. Practices that build a pre-submission checklist around these items reduce their denial rate substantially.

• Missing NDC: No NDC or invalid NDC format on Medicare Part B claims is a hard reject. Verify 11-digit format, N4 qualifier, UN unit of measure, and quantity before submission.
• Wrong billing unit: Billing multiple units of J7321 on a single date of service for one injection triggers MUE (Medically Unlikely Edit) flags. One visit, one unit.
• Missing medical necessity documentation: LCD requirements for conservative treatment failure must be documented in the patient record. A bare osteoarthritis diagnosis without prior treatment notes is insufficient.
• Incorrect product code: Billing J7321 for Euflexxa (J7323), Orthovisc (J7324), or Synvisc (J7325) is a misrepresentation. Verify the exact product dispensed against the HCPCS code before submitting.

Maintaining a structured documentation workflow for drug injection billing reduces these gaps before a claim is submitted. The structured approach used for other injectable drug billing codes like IVF codes applies equally here: confirm the product, confirm the code, confirm the NDC, confirm the medical necessity note is in the chart.

How Pabau supports J7321 billing workflows

Orthopedic and rheumatology practices running viscosupplementation programs need billing workflows that handle drug code pairing, NDC data capture, and payer-specific documentation requirements without manual rework at each step. Pabau’s claims management software supports structured billing workflows that reduce the common J7321 denial triggers described above.

Practices using Pabau can configure pre-built treatment protocols that associate J7321 with CPT code 20610, prompt staff to record the dispensed product’s NDC at the point of care, and flag incomplete documentation before a claim leaves the practice. For multi-location practices running viscosupplementation across several sites, Pabau’s reporting tools provide visibility into claim status and denial patterns by location. Explore how practice management software centralizes these workflows across a multi-provider practice.

Conclusion

J7321 is a per-dose HCPCS code covering Hyalgan, Supartz, and Visco-3 for knee osteoarthritis injections. Three requirements drive the majority of successful claims: pairing J7321 with CPT 20610, submitting a valid NDC on every Medicare Part B claim, and maintaining LCD-compliant medical necessity documentation in the patient record. Getting any one of these wrong is the single most common reason viscosupplementation claims are denied or delayed.

Pabau’s claims management tools help orthopedic and rheumatology practices build those requirements into the workflow so billing staff are not catching errors at submission. To see how Pabau handles drug code billing from chart to claim, book a demo.

Continue your research

Managing injectable drug billing across your practice? Claims management software helps orthopedic practices reduce J-code denials and track drug claim status from submission to payment.

Need to document viscosupplementation treatment plans? Digital documentation forms capture lot numbers, NDC data, and medical necessity notes at the point of care.

Running a multi-location orthopedic or sports medicine practice? Sports medicine software from Pabau centralizes scheduling, billing, and compliance documentation across sites.

Frequently Asked Questions